Nutrition and Metabolic Insights

Background: We have recently noted an acute increase in circulating free fatty acids and glycerol, as well as resting metabolic rate, when men and women ingested the dietary supplement OxyELITE Pro™ in a single dose. We have also noted a reduction in appetite when subjects were treated with this supplement for 14 consecutive days. It is possible that such findings may favor body weight and fat loss over time. Therefore, the purpose of the present study was to determine the effects of this dietary supplement on weight loss and associated markers using an eight week intervention.

Methods: Exercise-trained subjects were randomly assigned in double blind manner to ingest either the dietary supplement (n = 16; aged 22.8 ± 0.7) or a placebo (n = 16; 22.5 ± 0.5) every day for eight weeks. Body weight, body composition, skinfold thickness, serum lipids, and appetite were measured as the primary outcome variables. As measures of supplement safety, a complete blood count and comprehensive metabolic panel were performed, and resting heart rate and blood pressure were measured (pre and post intervention).

Results: No interactions or main effects were noted for our primary outcome measures (P > 0.05). However, when comparing pre and post intervention values for the supplement, significant decreases were noted in appetite, body weight, body fat percentage, and skinfold thickness (P < 0.05), while increases were noted for total and HDL-C, as well as for resting heart rate (P < 0.05). No changes were noted for placebo from pre to post intervention (P > 0.05), with the exception of an increase in HDL-C (P < 0.05). Blood pressure and bloodborne safety variables were not differently impacted by supplement or placebo (P > 0.05), with the exception of monocytes, for which an interaction effect was noted (P = 0.04).

Conclusion: These data indicate that the dietary supplement OxyELITE Pro™ may assist in weight and body fat loss in a sample of exercise-trained men and women. The supplement does not result in any adverse effects pertaining to resting blood pressure or bloodborne markers of safety; however a small increase in resting heart rate is observed.